PL2162149T3 - Szczepionka do zapobiegania nawrotowi raka sutka - Google Patents

Szczepionka do zapobiegania nawrotowi raka sutka

Info

Publication number
PL2162149T3
PL2162149T3 PL08745615T PL08745615T PL2162149T3 PL 2162149 T3 PL2162149 T3 PL 2162149T3 PL 08745615 T PL08745615 T PL 08745615T PL 08745615 T PL08745615 T PL 08745615T PL 2162149 T3 PL2162149 T3 PL 2162149T3
Authority
PL
Poland
Prior art keywords
recurrence
vaccine
prevent
breast cancer
breast
Prior art date
Application number
PL08745615T
Other languages
English (en)
Inventor
George E Peoples
Ponniah Sathibalan
Original Assignee
Henry M Jackson Found Advancement Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found Advancement Military Medicine Inc filed Critical Henry M Jackson Found Advancement Military Medicine Inc
Publication of PL2162149T3 publication Critical patent/PL2162149T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08745615T 2007-06-01 2008-04-11 Szczepionka do zapobiegania nawrotowi raka sutka PL2162149T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
PCT/US2008/060044 WO2008150577A1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse
EP08745615.8A EP2162149B1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Publications (1)

Publication Number Publication Date
PL2162149T3 true PL2162149T3 (pl) 2014-04-30

Family

ID=40094045

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08745615T PL2162149T3 (pl) 2007-06-01 2008-04-11 Szczepionka do zapobiegania nawrotowi raka sutka

Country Status (16)

Country Link
US (6) US8222214B2 (pl)
EP (2) EP2162149B1 (pl)
JP (6) JP5635399B2 (pl)
KR (5) KR102079921B1 (pl)
CN (2) CN101678093A (pl)
AU (1) AU2008260399C1 (pl)
CA (1) CA2687368C (pl)
CY (1) CY1114912T1 (pl)
DK (1) DK2162149T3 (pl)
ES (1) ES2445399T3 (pl)
HR (1) HRP20140102T1 (pl)
MX (1) MX2009012858A (pl)
PL (1) PL2162149T3 (pl)
PT (1) PT2162149E (pl)
SI (1) SI2162149T1 (pl)
WO (1) WO2008150577A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2008150577A1 (en) * 2007-06-01 2008-12-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
BRPI0922849B1 (pt) 2008-12-10 2023-01-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Composição de vacina com uma quantidade eficaz de um peptídeo gp2 e de gm-csf
US9814767B2 (en) 2012-02-17 2017-11-14 Mayo Foundation For Medical Education And Research Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
US10028918B2 (en) 2012-05-08 2018-07-24 Albert Einstein College Of Medicine, Inc. Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP2762158A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
US20140220079A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015066020A1 (en) * 2013-10-28 2015-05-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
WO2015127027A1 (en) * 2014-02-20 2015-08-27 Wayne State University Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
MX2018009228A (es) 2016-01-29 2019-07-08 Sorrento Therapeutics Inc Proteínas de unión a antigeno que se unen a pd-l1.
WO2017210255A1 (en) 2016-05-31 2017-12-07 Galena Biopharma, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
KR20210104672A (ko) * 2018-10-21 2021-08-25 에스엘에스지 리미티드 엘엘씨 삼중음성 유방암의 치료를 위한 병용 면역요법
JP2024515574A (ja) 2021-05-04 2024-04-10 アストン エスシーアイ． インコーポレイテッド Ｈｅｒ２ワクチン組成物
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
FI972514A7 (fi) * 1994-12-14 1997-08-12 Scripps Research Inst Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) * 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1246597B1 (en) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
AU7743100A (en) * 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
WO2003004609A2 (en) * 2001-07-03 2003-01-16 Lexicon Genetics Incorporated Novel human kielin-like proteins and polynucleotides encoding the same
NZ530315A (en) * 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
EP1482963A4 (en) 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
PT1553966E (pt) * 2002-10-03 2012-10-22 Wyeth Corp Péptidos de fusão que compreendem os polipéptidos e7 e e6 do vírus do papiloma humano e as composições imunogénicas dos mesmos
JP2007523599A (ja) 2003-02-10 2007-08-23 オートゲン リサーチ ピーティーワイ エルティーディー． 治療用分子
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005014634A1 (en) * 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
WO2008150577A1 (en) * 2007-06-01 2008-12-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse

Also Published As

Publication number Publication date
EP2162149A1 (en) 2010-03-17
EP2722336A1 (en) 2014-04-23
CA2687368A1 (en) 2008-12-11
EP2162149B1 (en) 2013-11-06
JP6097724B2 (ja) 2017-03-15
EP2162149A4 (en) 2012-07-25
KR20180061412A (ko) 2018-06-07
US20100209443A1 (en) 2010-08-19
US20220347281A1 (en) 2022-11-03
US8796220B2 (en) 2014-08-05
US9370560B2 (en) 2016-06-21
AU2008260399C1 (en) 2014-07-17
SI2162149T1 (sl) 2014-04-30
JP2018199691A (ja) 2018-12-20
JP2021001218A (ja) 2021-01-07
CN105816867A (zh) 2016-08-03
KR102283639B1 (ko) 2021-08-02
MX2009012858A (es) 2010-02-03
HRP20140102T1 (hr) 2014-03-28
JP7072467B2 (ja) 2022-05-20
JP2010529026A (ja) 2010-08-26
KR102079921B1 (ko) 2020-02-21
KR20150106870A (ko) 2015-09-22
JP2014237653A (ja) 2014-12-18
AU2008260399A1 (en) 2008-12-11
CY1114912T1 (el) 2017-01-25
JP5635399B2 (ja) 2014-12-03
US20190060429A1 (en) 2019-02-28
AU2008260399B2 (en) 2014-01-16
US10842856B2 (en) 2020-11-24
DK2162149T3 (da) 2014-02-10
CN101678093A (zh) 2010-03-24
AU2008260399A8 (en) 2010-01-07
WO2008150577A1 (en) 2008-12-11
KR101572474B1 (ko) 2015-11-30
US20220241389A1 (en) 2022-08-04
JP2022095926A (ja) 2022-06-28
JP2017071607A (ja) 2017-04-13
KR20100027187A (ko) 2010-03-10
US8222214B2 (en) 2012-07-17
KR20210097209A (ko) 2021-08-06
PT2162149E (pt) 2014-02-12
ES2445399T3 (es) 2014-03-03
US20150182609A1 (en) 2015-07-02
US20130189290A1 (en) 2013-07-25
KR20200019776A (ko) 2020-02-24
CA2687368C (en) 2018-10-30
KR101863534B1 (ko) 2018-06-04

Similar Documents

Publication Publication Date Title
PL2162149T3 (pl) Szczepionka do zapobiegania nawrotowi raka sutka
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
LTPA2018013I1 (lt) Antivirusinė terapija
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012005594A2 (pt) tratamento de câncer
EP2480230A4 (en) DR5 Ligand-HEILMITTELKONJUGATE
ES2638522T8 (es) Procedimientos para detectar cáncer
EP2448439A4 (en) SHIRT
DK2114993T3 (da) Vaccine
IL225441A0 (en) Breast cancer diagnostics
EP2544753A4 (en) CATHETER ARRANGEMENT
EP2283862A4 (en) ANTITUMOR AGENT
EP2428690A4 (en) TERMINAL
EP2603516A4 (en) SYNTHESIS OF 2'-DESOXY-2 '- [18F-] FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU)
DK2292197T3 (da) Vandresistent plaster
BRPI0922849A2 (pt) vacina para a prevenção de recorrência de câncer de mama
EP2615946A4 (en) ADJUSTABLE CHILD SEAT
GB201003293D0 (en) Cancer vaccine
EP2486929A4 (en) THERAPEUTICS FOR TUMOR
EP2659886A4 (en) Patch
GB0910751D0 (en) Prostate cancer vaccine
HUE059408T2 (hu) Természetes gyógyászati vegyület
FR2953122B1 (fr) Prothese mammaire
DK2243032T3 (da) RBM3 som markør for brystkræftprognose
GB0720156D0 (en) Breast cancer associated antigen